Cognitive Recovery With Cannabis Abstinence Among High School-Aged Adolescents
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03276221|
Recruitment Status : Recruiting
First Posted : September 8, 2017
Last Update Posted : September 8, 2017
|Condition or disease||Intervention/treatment|
|Cannabis Use Cognitive Change Adolescent Behavior||Behavioral: Abstinence|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||210 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||Cannabis users are randomized either to 30 days of cannabis abstinence or 30 days of monitoring with no abstinence requirement. Non-users are not randomized.|
|Masking:||None (Open Label)|
|Official Title:||Cognitive Recovery With Cannabis Abstinence Among High School-Aged Adolescents|
|Actual Study Start Date :||August 1, 2017|
|Estimated Primary Completion Date :||January 31, 2022|
|Estimated Study Completion Date :||January 31, 2022|
Active Comparator: Abstinent
This group of cannabis users are agree to remain abstinent from cannabis use for 30 days.
Cannabis users randomized to this condition will be enrolled in a contingency management intervention for 30 days of cannabis abstinence.
Other Name: Contingency Management
No Intervention: Monitoring
This group of cannabis users are not asked to change their cannabis use behavior.
No Intervention: Non-Users
This is a group of adolescents with little to no cannabis use history and is non-randomized.
- Change in Memory Measured with the CANTAB [ Time Frame: From Baseline to 30 days ]
- Change in Attention Measured with the CANTAB [ Time Frame: From Baseline to 30 days ]
- Change in Executive Functioning Measured with the CANTAB [ Time Frame: From Baseline to 30 days ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03276221
|Contact: Randi M Schuster, PhD||617-643-6673||Rschuster@mgh.harvard.edu|
|United States, Massachusetts|
|Massachusetts General Hospital||Recruiting|
|Boston, Massachusetts, United States, 02114|
|Contact: Randi M Schuster, PhD 617-643-6673 Rschuster@mgh.harvard.edu|
|Principal Investigator: Randi M Schuster, PhD|
|Principal Investigator:||Randi M Schuster, PhD||Massachusetts General Hospital|